CN Patent

CN101583359A — 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途

Assigned to Celgene Corp · Expires 2009-11-18 · 16y expired

What this patent protects

本发明公开了通过施用被称为Revlimid或来那度胺的本发明的免疫调节化合物来治疗、预防或控制套细胞淋巴瘤。本发明进一步涉及该化合物联合化学治疗、放射治疗、激素治疗、生物治疗或免疫治疗在所述治疗中的用途。本发明还公开了适用于本发明的药物组合物和单独的单位剂型。

USPTO Abstract

本发明公开了通过施用被称为Revlimid或来那度胺的本发明的免疫调节化合物来治疗、预防或控制套细胞淋巴瘤。本发明进一步涉及该化合物联合化学治疗、放射治疗、激素治疗、生物治疗或免疫治疗在所述治疗中的用途。本发明还公开了适用于本发明的药物组合物和单独的单位剂型。

Drugs covered by this patent

Patent Metadata

Patent number
CN101583359A
Jurisdiction
CN
Classification
—
Expires
2009-11-18
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.